Exosome therapy developer Codiak Biosciences – based on research at Gothenburg and MD Anderson Cancer Center – has filed to raise up to $100m.
Codiak Biosciences, a US-based exosome drug developer, refiled for an initial public offering on Wednesday.
The company had previously filed to raise up to $86.3m in an offering on the Nasdaq Global Select Market in April 2019 before withdrawing its application three months later. It has now set an initial target of $100m for an IPO on the same market.
Founded in 2015, Codiak is developing drugs to treat diseases with high unmet medical need…
